Cynthia A Robinson

Address:

424 Cornwall Ave, Buffalo, NY 14215

VIN:

1FAHP35N89W248520

Make:

FORD

Model:

FOCUS

Year:

2009

US Patent:

20200054627, Feb 20, 2020

Filed:

Oct 28, 2019

Appl. No.:

16/665715

Inventors:

- Morristown NJ, US
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/48
A61K 9/50
A61K 9/00
A61K 9/16

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20180338966, Nov 29, 2018

Filed:

Jul 23, 2018

Appl. No.:

16/042196

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/50
A61K 9/48
A61K 9/16
A61K 9/00

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20170202831, Jul 20, 2017

Filed:

Apr 3, 2017

Appl. No.:

15/477561

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/48
A61K 9/00

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20170042885, Feb 16, 2017

Filed:

Nov 1, 2016

Appl. No.:

15/340502

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/00

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20160354365, Dec 8, 2016

Filed:

Aug 22, 2016

Appl. No.:

15/243432

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/48
A61K 9/00
A61K 9/50

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20160263107, Sep 15, 2016

Filed:

May 20, 2016

Appl. No.:

15/160359

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/50
A61K 9/48
A61K 9/00

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20160256455, Sep 8, 2016

Filed:

May 13, 2016

Appl. No.:

15/154527

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/16
A61K 9/50
A61K 9/00
A61K 9/48

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment

US Patent:

20160250207, Sep 1, 2016

Filed:

May 13, 2016

Appl. No.:

15/154524

Inventors:

- Dublin, IE
Christopher M. Rubino - Williamsville NY, US
Cynthia Y. Robinson - Burlingame CA, US

International Classification:

A61K 31/485
A61K 9/48
A61K 9/50
A61K 9/00

Abstract:

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment